


# MD Anderson at ESMO

SEPT. 13-17 | BARCELONA, SPAIN

MDAnderson.org/ESMO



**Friday, September 13** **As of September 3.**

13:00-13:30 CEST 6:00-6:30 a.m. CDT	Meet the Experts: Insights on Breast Cancer Mariana Chavez Mac Gregor, M.D., and Giancarlo Moscol, M.D.	MD Anderson Booth 624
14:00-15:30 CEST 7:00-8:30 a.m. CDT	Proffered paper session 1: GU tumours, non-prostate	
15:00-15:10 CEST 8:00-8:10 a.m. CDT	16900-NKT2152, a novel oral HIF-2 $\alpha$ inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a Phase I/II study	Eric Jonasch, M.D.
15:20-15:30 CEST 8:20-8:30 a.m. CDT	Q&A	
16:00-17:30 CEST 9:00-10:30 a.m. CDT	Special symposium: Lung cancer interception: New approaches to lung cancer screening and prevention	Bilbao Auditorium - Hall 2
16:35-16:50 CEST 9:35-9:50 a.m. CDT	Immunotherapy and beyond for lung cancer prevention	Jianjun Zhang, M.D., Ph.D.
17:05-17:25 CEST 10:05-10:25 a.m. CDT	Q&A and discussion	
16:00-17:30 CEST 9:00-10:30 a.m. CDT	Proffered paper session 1: Developmental therapeutics	Santander Auditorium - Hall 5
16:50-17:00 CEST 9:50-10 a.m. CDT	6060-Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatumab) in patients with advanced/metastatic solid tumors	Funda Meric-Bernstam, M.D.
16:30-17:00 CEST 11:30 p.m.-midnight	Meet the Experts: Early Phase Clinical Trials at MD Anderson David Hong, M.D., and Aung Naing, M.D.	MD Anderson Booth 624
Posters		
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis		David Hong, M.D.
629P - Phase I Study of Pamiparib and Cabozantinib in Patients with Metastatic Solid Tumors Harboring Homologous Recombination Deficiency (HRD)		Siqing Fu, M.D.

**Saturday, September 14**

10:00-10:30 CEST 3:00-3:30 a.m. CDT	Meet the Experts: Career Opportunities at MD Anderson Giulio Draetta, M.D., Ph.D., and Jennifer Litton, M.D.	MD Anderson Booth 624
10:30-11 CEST 3:30-4 a.m. CDT	Meet the Experts: New Horizons in Lung Cancer Treatment Xiuning Le, M.D., Ph.D.	
11-11:30 CEST 3:30-4 a.m. CDT	Meet the Experts: Spotlight on Sarcoma Anthony Conley, M.D., and Elise Nassif Haddad, M.D., Ph.D.	
13-13:30 CEST 6:00-6:30 a.m. CDT	Meet the Experts: MD Anderson Cancer Network® Michael Overman, M.D.	
	Meet the Experts: Patient-Centered Palliative Care David Hui, M.D.	

14:45-16:15 CEST 7:45-9:15 a.m. CDT	Mini oral session: GI tumours, lower	Granada Auditorium - Hall 6
15:20-15:25 CEST 8:20-8:25 a.m. CDT	510MO - Long-Term Survival and Organ Preservation with Pembrolizumab in Localized MSI-H/dMMR Solid Tumors	Kaysia Ludford, M.D.
14:45-16:15 CEST 7:45-9:15 a.m. CDT	Mini oral session: Developmental therapeutics	Oviedo Auditorium - Hall 3
15:40-15:45 CEST 8:40-8:45 a.m. CDT	618MO - Phase Ib/2 first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2-metastatic breast cancer and advanced solid tumors	Timothy Yap, M.B.B.S., Ph.D.
14:45-16:25 CEST 7:45-9:15 a.m. CDT	Proffered paper session: Supportive and palliative care	Pamplona Auditorium - Hall 3
15:42-15:52 CEST 8:42-8:52 a.m. CDT	1476O-Haloperidol and Lorazepam for Agitated Delirium in Patients with Advanced Cancer: A Multicenter, Double-Blind, Randomized Clinical Trial (RCT)	David Hui, M.D.
16:17-16:25 CEST 9:17-9:25 a.m. CDT	Q&A	
Posters		
620P - Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with tumor mutational burden-high (TMB-H) and/or microsatellite instability-high (MSI-H) cancers: Results from an expansion cohort		Aung Naing, M.D.
638P - Final Results of IMPACT 2, a Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer at MD Anderson Cancer Center		Apostolia Tsimberidou, M.D., Ph.D.
900P - Notch inhibitor AL101 prior to surgery in patients (pts) with Notch1-activated adenoid cystic carcinoma (ACC): Safety and efficacy in a window of opportunity study		Renata Ferrarotto, M.D.
1024P - Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors		Stéphane Champiat, M.D., Ph.D.
1024P - Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors		
1089P - Longitudinal biomarker analysis and outcomes for patients (pts) treated with neoadjuvant nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma		Elizabeth Burton
1264P - Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need		John Heymach, M.D., Ph.D.
1298P - Epidemiological and genomic features of patients (pts) with advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with HER2/ERBB2 mutations within and outside the tyrosine kinase domain (TKD)		Xiuning Le, M.D., Ph.D.
1303P - METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker presence		
1305P - Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials		Ferdinandos Skoulidis, M.D., Ph.D.
1325P - TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial		
1756P - A Phase I/II trial of gemcitabine, docetaxel, and hydroxychloroquine in advanced/metastatic osteosarcoma		Andrew Livingston, M.D.
1777P - Molecular profiling from next-generation sequencing (NGS) reveals new potential therapeutic targets in patients with pediatric-type sarcomas		Anthony Conley, M.D.

1778P - Clear cell sarcomas (CCS) express Gp100, a novel immune target for a bispecific T cell engager		Elise Nassif Haddad, M.D., Ph.D.
1915P - Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma		Matthew Ning, M.D.
<b>Sunday, September 15</b>		
08:30-10:00 CEST 1:30-3 a.m. CDT	Special symposium: Next generation of combinations in early clinical trials	Santander Auditorium - Hall 5
09:20-09:35 CEST 2:20-2:35 a.m. CDT	DDR inhibitor combinations	Timothy Yap, M.B.B.S., Ph.D.
10:15-11:45 CEST 3:15-4:45 a.m. CDT	Mini oral session: Supportive and palliative care	Toledo Auditorium - Hall 3
11:10-11:15 CEST 4:10-4:15 a.m. CDT	1821MO-Predictive biomarkers of dyspnea response to dexamethasone in cancer patients: A secondary analysis of the Alleviating Breathlessness in Cancer Patients with Dyspnea (ABCD) trial	David Hui, M.D.
10:15-11:45 CEST 3:15-4:45 a.m. CDT	Mini oral session: Non-metastatic NSCLC	Barcelona Auditorium - Hall 2
	Chair	
11:15-11:30 CEST 4:15-4:30 a.m. CDT	Invited Discussant 1910MO and 1240MO	Jia Wu, Ph.D.
10:00-10:30 CEST 3:00-3:30 a.m. CDT	Meet the Experts: Advances in Gynecologic Cancers Amir Jazaeri, M.D.	MD Anderson Booth 624
10:30-11:00 CEST 3:30-4 a.m. CDT	Meet the Experts: Advances in Immunotherapy Adam Grippin, M.D., Ph.D., and Kaysia Ludford, M.D.	
13:00-13:30 CEST 3:30-4 a.m. CDT	Meet the Experts: Emerging Frontiers in Cellular Therapies Katy Rezvani, M.D., Ph.D.	
14:45-16:15 CEST 7:45-9:15 a.m. CDT	Educational session: Gene modified T cells and new players	Burgos Auditorium - Hall 5
	Chair	
15:10-15:35 CEST 8:20-8:35 a.m. CDT	CAR NK Cells	Katy Rezvani, M.D., Ph.D.
16:00-16:15 CEST 9:00-9:15 a.m. CDT	Q&A	
15:00-15:30 CEST 8:00-8:30 a.m. CDT	Meet the Experts: Kidney Cancer—What's New, What's Next Eric Jonasch, M.D.	MD Anderson Booth 624
Posters		
11P - Therapeutic effects of MRTX1133 in KRAS G12D mutant appendiceal cancer: Insights from organoid and in vivo studies		John Paul Shen, M.D.
190P - A large scale proteogenomics atlas for precision oncology research		Timothy Yap, M.B.B.S., Ph.D.
<b>Monday, September 16</b>		
08:30-10:00 CEST 1:30-3:00 a.m. CDT	Educational session: Protein degradation as a novel approach for cancer therapy	Granada Auditorium - Hall 6
08:30-08:55 CEST 1:30-1:55 a.m. CDT	Targeted protein degradation: Pharmacological aspects	Jordi Rodon Ahnert, M.D., Ph.D.
09:45-10:00 CEST 2:45-3:00 a.m. CDT	Q&A	
08:30-10:00 CEST 1:30-3:00 a.m. CDT	Mini oral session: Basic science and translational research	Valencia Auditorium - Hall 5

09:00-9:05 CEST 1:00-1:05 a.m. CDT	71MO - Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: A phase I/II trial	Salah-Eddine Bentebibel, Ph.D.
10:15-11:30 CEST 3:15-4:30 a.m. CDT	Multidisciplinary session: Updates in the management of advanced renal cell carcinoma	Bilbao Auditorium - Hall 2
10:40-11:00 CEST 3:40-4:00 a.m. CDT	Is there a role for radiation therapy in advanced RCC?	Chad Tang, M.D.
10:15-11:45 CEST 3:15-4:45 a.m. CDT	Mini oral session: Investigational immunotherapy	Granada Auditorium - Hall 6
10:25-10:30 CEST 3:25-3:30 a.m. CDT	995MO - Association of SARS-COV-2 mRNA vaccines with tumor PD-L1 expression and clinical responses to immune checkpoint blockade	Adam Grippin, M.D., Ph.D.
11:00-11:30 CEST 4:00-4:30 a.m. CDT	Meet the Experts: Gastrointestinal Cancers: The Latest Advances Christine Parseghian, M.D.	MD Anderson Booth 624
11:30-12:00 CEST 4:30-5:00 a.m. CDT	Meet the Experts: The Future of Radiation Oncology Matthew Ning, M.D., and Chad Tang, M.D.	
Posters		
287P - Cognitive impairment in older breast cancer survivors		Sharon Giordano, M.D.
308P - Impact of the COVID-19 (C19) pandemic on breast cancer (BC) treatment patterns in the US		Mariana Chavez Mac Gregor, M.D.
337P - Is presence of molecular residual disease after pathologic complete response associated with relapse in inflammatory breast cancer?		Jennifer Chen, M.D.
413P - Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2- metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors		Timothy Yap, M.B.B.S., Ph.D.
427P - The role of patient navigation (PN) in delivering goal-concordant care to advanced breast cancer (ABC) patients		Akshara Raghavendra, M.D.
985P - Analysis of antidrug antibodies (ADA) to camrelizumab in CARES-310: The pivotal phase III study of camrelizumab + rivocecanib in unresectable hepatocellular carcinoma (uHCC)		Ahmed Kaseb, M.D.
1531TiP - TWINPEAK Phase I/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and/or pembrolizumab in gastric/GEJ-carcinomas or PDAC		Michael Overman, M.D.